With the recent approvals of all three major anti-IL-23p19 assets in at least one of the IBD indications, ECCO 2025 will provide critical insights into their future market trajectories.
general market analysis and risk management together build a strong foundation for investment success. Bill O'Neil used these pillars for decades. When IBD launched in 1984, they became the ...